1. Volume 3, Issue 12, Pages 1138-1146 (December 2016)
Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials 
Dr Alexander McGirr, MD, Paul A Vöhringer, MD, S Nassir Ghaemi, MD, Raymond W Lam, MD, Prof Lakshmi N Yatham, MBBS 
The Lancet Psychiatry 
Volume 3, Issue 12, Pages (December 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1 Study selection
CENTRAL=Cochrane Central Register of Controlled Trials.
The Lancet Psychiatry 2016 3, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2 Clinician-rated depressive symptoms
STEP-BD13 data are presented at 6 weeks. SMD=standardised mean difference.
The Lancet Psychiatry 2016 3, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

4. Figure 3 (A) Clinical response and (B) clinical remission
OR=odds ratio.
The Lancet Psychiatry 2016 3, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

5. Figure 4 Treatment-emergent affective switches
(A) Acute treatment. (B) 52 week extensions. OR=odds ratio.
The Lancet Psychiatry 2016 3, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions